Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Pharmaceutical GLP-1 receptor agonists are licensed for type 2 diabetes and specific obesity indications according to NICE guidance, requiring GP consultation and monitoring
Early rodent studies showed an increased rate of C-cell tumors after prolonged GLP-1 exposure
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
To determine whether the improved PK properties of the QMP-engineered fusions would translate into enhanced efficacy, we repeated the GTT in human FcRn Tg32 mice
US$ 27.54
US$ 24.54
US$ 20.26
US$ 21.37
US$ 20.65
US$ 27.99
US$ 24.18
